Fingerprint
Dive into the research topics of 'Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically